Global pharmaceutical company Eli Lilly & Co. NYSE: LLY has been in a GLP-1 arms race with its FDA-approved therapies Mounjaro and Zepbound. It's been going heads-up against GLP-1 leader Novo Nordisk A/S NYSE: NVO, best known for Ozempic and Wegovy.Eli Lilly and Company TodayLLYEli Lilly and Company$918.00 +3.43 (+0.38%) 52-Week Range$434.34▼$928.60Dividend Yield0.57%P/E Ratio135.20Price Target$816.78Add to WatchlistBy all accounts, Eli Lilly's Tirzepatide, the active ingredient in Mounjaro and Zepbound, is ...

Eli Lilly and Company Today LLY Eli Lilly and Company $904.76 -0.62 (-0.07%) 52-Week Range $434.34 ▼ $915.79 Dividend Yield 0.57% P/E Ratio 133.25 Price Target $812.72 Add to Watchlist Global pharmaceutical giant Eli Lilly & Co. NYSE: LLY has made headlines with its leading GLP-1 weight loss drugs, Mounjaro and Zepbound. Mounjaro is prescribed for Type 2 diabetes but is often used off-label for weight loss. Zepbound is prescribed for obesity treatment. The active ingredient in both is Tirzepatide. Lilly sub ...

tiratus phaesuwan/iStock via Getty Images Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) suffered a major setback this year when it voluntarily delisted its Amyotrophic lateral sclerosis [ALS] drug Relyvrio on April 4th of 2024. This was a huge blow to the company, definitely, but that doesn't mean that it doesn't have some opportunities to redeem itself in the coming years. What I'm talking about is that it is using AMX0035 for other indications. This particular drug is being developed to treat patients with W ...

New research confirms behavior change driven by Dario digital platform is sustainable for 12 month period and supports clinical results for members taking a GLP-1 Additional research demonstrates 31% of Dario members with Type 2 diabetes achieve results reflecting diabetes remission NEW YORK, June 25, 2024 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today two new studies presented this past weekend at the 84th Annual Am ...

~ New RT-114 obesity program combines ProGen’s FC Fusion protein conjugated GLP-1/GLP-2 dual agonist, PG-102, with the RaniPill® capsule designed to provide a differentiated oral delivery mechanism with bioavailability comparable to subcutaneous injection ~ ~ Rani and ProGen to share responsibilities for the development and commercialization of RT-114, including a 50/50 cost and revenue share arrangement ~ ~ Rani to host conference call today at 8:00 a.m. ET/5:00 a.m. PT ~ SAN JOSE, Calif., June 24, 2024 (G ...

Most of the market focuses on the technology sector, with names like Nvidia Co. NASDAQ: NVDA receiving the lion's share. Among this hype and excitement, those companies worthy of investor capital have been left behind, particularly those in the 'defensive' space, such as the healthcare sector. Eli Lilly and Company Today LLY Eli Lilly and Company $891.46 +6.45 (+0.73%) 52-Week Range $434.34 ▼ $894.87 Dividend Yield 0.58% P/E Ratio 131.29 Price Target $787.53 Add to Watchlist Those savvy enough to decrypt th ...

Editor's note: Seeking Alpha is proud to welcome Evan Urbanski as a new contributing analyst. You can become one too! Share your best investment idea by submitting your article for review to our editors. Get published, earn money, and unlock exclusive SA Premium access. Click here to find out more » ...

文章核心观点 - 艾伯维公司的糖尿病和减肥药物需求激增,带动公司业绩大幅增长[1][2][3] - 公司正在大幅投资扩大生产规模,以满足不断增长的市场需求[5][6][7] 行业概况 - 公司生产的GLP-1激动剂类药物是一种新兴的糖尿病和减肥治疗方法,市场规模有望在未来10年内达到1000亿美元[4] - 艾伯维和竞争对手诺和诺德都面临着无法满足市场旺盛需求的挑战,导致这类药物出现全国性短缺[3] 公司经营情况 - 艾伯维公司新任CFO阿纳特·阿什肯纳兹在过去一年中发挥了关键作用,成功管理了公司糖尿病药物Mounjaro和新上市的减肥药Zepbound带来的收入暴增和投资者热情[2] - 公司正在大幅投资扩大生产规模,以满足不断增长的市场需求,但预计短期内仍无法完全满足[5][6][7]

Key Points Hims & Hers operates a direct-to-consumer (DTC) telehealth platform for health and beauty, ED, hair loss, weight loss and non-urgent primary care needs. Hims & Hers reported a blowout Q1 2024 top and bottom line beat and raised the forecast for 2024. Hims & Hers announced they would start selling compounded GLP-1 (Semaglutide) for weight loss, a non-FDA-approved generic version of Ozempic and Wegovy. 5 stocks we like better than Hims & Hers Health Him & Hers Health Inc. NYSE: HIMS provides a dire ...

文章核心观点 - 新型GLP-1类药物Wegovy是一种有效的减肥药,但专利保护将在本十年内到期 [1] - 随着GLP-1类药物需求激增,多家数字健康公司正在推出相关服务和项目,以期从中获利 [7][9] - 但供应短缺和保险报销问题仍是行业面临的主要挑战 [11][39][40] 公司总结 Ro公司 - Ro公司原本是一家专注于治疗勃起功能障碍的公司,后转向肥胖管理业务 [12][13] - Ro公司推出了"Ro Body Program",为患者提供GLP-1类药物和配套服务 [5][6][35][36][37][46][47] - Ro公司在供应短缺期间采取了一系列措施来帮助患者获得药物 [35][36][37][38] WeightWatchers公司 - WeightWatchers公司推出了新的GLP-1类药物支持项目,为患者提供专业指导 [18][19][20][21][22] - 但WeightWatchers公司整体业务仍面临挑战,股价大幅下跌 [23] Calibrate公司 - Calibrate公司是较早推出GLP-1类药物+辅助服务的公司之一 [26][27][28][29][30][31][32][33][34] - 该公司在过去两年遭遇了供应短缺、保险报销等问题,最终被私募基金收购 [31][32][33] Hims & Hers公司 - Hims & Hers公司最初未涉足GLP-1类药物市场,后来推出了自有的复合GLP-1注射剂 [42][43][44][45] - 该公司认为口服药物也是一种有效的替代选择 [42][43]